Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia ( ITP ) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia ( ITP ) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies

Published:2019-02-21 Issue:3 Volume:185 Page:503-513
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kuter David J.¹^ORCID,Newland Adrian²,Chong Beng H.³,Rodeghiero Francesco⁴⁵,Romero Monica T.⁶,Pabinger Ingrid⁷,Chen Yuqi⁸,Wang Kejia⁸,Mehta Bhakti⁸,Eisen Melissa⁸

Affiliation:

1. Department of Hematology Massachusetts General Hospital Boston MA USA

2. The Pathology Clinical Academic Group the Royal London Hospital London UK

3. University of New South Wales and St. George Hospital Sydney Australia

4. Hematology Project Foundation Vicenza Italy

5. San Bortolo Hospital Vicenza Italy

6. Hospital Juárez de México México CityMéxico

7. Medizinische Universitat Wien ViennaAustria

8. Amgen Inc. Thousand Oaks CA USA

Funder

Amgen

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15803

Reference36 articles.

1. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.

2. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia

3. AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP

4. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia

5. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment;Blood Reviews;2024-09

2. Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway;British Journal of Haematology;2024-08-05

3. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study;The Lancet Haematology;2024-08

4. A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia;New England Journal of Medicine;2024-06-20

5. Uso de romiplostim en trombocitopenia inmunitaria: experiencia en Cuenca (Ecuador);Biomédica;2024-05-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3